-- Confirms Full-Year Net Sales Guidance Range for the Neurology Franchise -- -- Raises Full-Year Earnings Guidance and Confirms Adjusted EBITDA Guidance -- -- Amends and Strengthens Commercial Agreement with Collegium -- -- Confirms Regulatory Plan to File for FDA Approval of Cosyntropin Depot by

LAKE FOREST, Ill. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that Phillip B. Donenberg, Senior Vice President and Chief Financial Officer, will retire effective November 30, 2018 . Replacing Mr. Donenberg will be Daniel A.

LAKE FOREST, Ill. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT), a leading specialty pharmaceutical company committed to advancing patient care, today announced that members of senior management will participate at the following investor conferences.

LAKE FOREST, Ill. , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release third-quarter 2018 financial results on Thursday, November 8, 2018 , after the close of markets. Following the announcement, the Company will host a conference call

LAKE FOREST, Ill. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT), a leading specialty pharmaceutical company committed to advancing patient care, today announced that members of senior management will participate at the 16 th Annual Morgan Stanley Global Healthcare

Purdue to pay Assertio $62 million in two installments LAKE FOREST, Ill. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that the Company has entered into a settlement agreement with Purdue Pharma L.P. with regard to the Company’s patent infringement

Name Change Reflects Company’s Focus on Neurology, Orphan and Specialty Businesses LAKE FOREST, Ill. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT), a leading specialty pharmaceutical company committed to advancing patient care, has announced that its corporate name

-- Raises Full-Year Earnings and Adjusted EBITDA Guidance Range and Lowers Full-Year Net Sales Guidance Range for the Neurology Franchise -- -- Confirms Regulatory Plan to File for FDA Approval of Cosyntropin Depot by Year End -- -- Announces Agreement with PDL BioPharma to Monetize Royalty Stream;

LAKE FOREST, Ill. , July 09, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release second-quarter 2018 financial results on Wednesday, August 8, 2018 , before the open of markets. Following the announcement, the Company will host a conference call beginning at

LAKE FOREST, Ill. , July 06, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) announced that effective July 3, 2018 , the Company granted ten newly-hired employees a total of 512,439 restricted stock units (“RSUs”).  The RSUs were granted as inducements material to each such individual’s entry